AbCellera Biologics (ABCL) Change in Receivables (2020 - 2026)

AbCellera Biologics has reported Change in Receivables for 7 years, with the latest figure at -$13.1 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 1256.49% year-over-year to -$13.1 million; the trailing twelve-month figure through Mar 2026 stood at $41.4 million (down 28.24% YoY), and the FY2025 full-year result was $55.6 million, down 25.95% from the prior year.
• Change in Receivables for Q1 2026 stood at -$13.1 million, down from $39.7 million in the prior quarter.
• The five-year high for Change in Receivables was $39.7 million in Q4 2025, with the low at -$13.1 million in Q1 2026.
• Historically, Change in Receivables has averaged $11.0 million across 5 years, with a median of $11.2 million in 2023.
• Annual changes were most pronounced in 2023 — Change in Receivables jumped 1900.0% — and 2026, when it sank 1256.49%.
• AbCellera Biologics' Change in Receivables stood at $19.0 million in 2022, then slumped by 45.18% to $10.4 million in 2023, then surged by 99.86% to $20.9 million in 2024, then soared by 90.14% to $39.7 million in 2025, then slumped by 133.03% to -$13.1 million in 2026.
• The last three Change in Receivables figures came in at -$13.1 million (Q1 2026), $39.7 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.